Abstract
Importance: Interpreting results from randomized clinical trials (RCTs) for COVID-19, which have been published rapidly and in vast numbers, is challenging during a pandemic.
Objective: To evaluate the robustness of statistically significant findings from RCTs for COVID-19 using the fragility index.
Design, setting, and participants: This cross-sectional study included COVID-19 trial articles that randomly assigned patients 1:1 into 2 parallel groups and reported at least 1 binary outcome as significant in the abstract. A systematic search was conducted using PubMed to identify RCTs on COVID-19 published until August 7, 2021.
Exposures: Trial characteristics, such as type of intervention (treatment drug, vaccine, or others), number of outcome events, and sample size.
Main outcomes and measures: Fragility index.
Results: Of the 47 RCTs for COVID-19 included, 36 (77%) were studies of the effects of treatment drugs, 5 (11%) were studies of vaccines, and 6 (13%) were of other interventions. A total of 138 235 participants were included in these trials. The median (IQR) fragility index of the included trials was 4 (1-11). The medians (IQRs) of the fragility indexes of RCTs of treatment drugs, vaccines, and other interventions were 2.5 (1-6), 119 (61-139), and 4.5 (1-18), respectively. The fragility index among more than half of the studies was less than 1% of each sample size, although the fragility index as a proportion of events needing to change would be much higher.
Conclusions and relevance: This cross-sectional study found a relatively small number of events (a median of 4) would be required to change the results of COVID-19 RCTs from statistically significant to not significant. These findings suggest that health care professionals and policy makers should not rely heavily on individual results of RCTs for COVID-19.
【초록키워드】 COVID-19, Treatment, randomized clinical trial, Vaccine, pandemic, Health care, Trial, Vaccines, cross-sectional, drugs, clinical trials, Intervention, outcome, RCT, Health, cross-sectional study, Characteristics, Care, trials, RCTs, Sample size, Abstract, not significant, parallel group, medians, participant, article, professional, robustness, fragility, COVID-19 RCTs, Effect, event, IQRs, identify, evaluate, proportion, reported, required, conducted, events, median, less, much higher, statistically significant, 1:1, COVID-19 RCT, Interpreting, IQR, randomly assigned patient, 【제목키워드】 COVID-19, clinical, fragility, Result, Significant,